Oncotarget

Research Papers:

Prognostic value of Flotillin-1 expression in patients with solid tumors

Yang-Xi Ou, Fang-Teng Liu, Fang-Ying Chen and Zheng-Ming Zhu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:52665-52677. https://doi.org/10.18632/oncotarget.17075

Metrics: PDF 1662 views  |   HTML 2357 views  |   ?  


Abstract

Yang-xi Ou1,*, Fang-teng Liu1,2,*, Fang-ying Chen3 and Zheng-ming Zhu1

1Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China

2Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, P. R. China

3The Health Centers of Fengzhou Town, Quanzhou 36200, Fujian Province, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Zhengming Zhu, email: [email protected]

Keywords: Flotillin-1, carcinoma, prognosis, meta-analysis

Received: December 21, 2016     Accepted: March 16, 2017     Published: April 13, 2017

ABSTRACT

Background: In numerous studies, Flotillin-1 was reported to be involved in tumor progression, indicating prognosis in various types of cancer. However, the results were inconsistent.

Results: A total of 2473 patients from 13 articles were included. The results indicated that: (1) Patients detected with high expression level of Flotillin-1 protein had a significantly shorter OS (HR =1.64; 95%CI: 1.39-1.88), statistical significance was also observed in subgroup meta-analyses stratified by the cancer type, nationality, detecting method, cutoff value, analysis type, sample size and publication date. (2) Patients with high Flotillin-1 protein expression level had a poorer DFS (HR = 2.49; 95%CI: 1.64-3.35), a worse RFS(HR = 3.26; 95%CI: 1.10-5.43) and a potential shorter PFS(HR = 1.84; 95%CI: 0.81-2.87). (3) The pooled odds ratios (ORs) showed that increased Flotillin-1 level was also related to lymph node metastasis (OR =6.30; 95% CI: 3.15-12.59), distant metastasis (OR =6.02; 95% CI: 1.50-24.06) and more advanced TNM stage (OR =4.69; 95% CI: 2.74-8.03).

Materials and methods: A comprehensive retrieval was performed in multiple databases, including PubMed, Embase, Web of Science and CNKI. The relevant articles were screened for investigating the association between increased Flotillin-1 expression level and prognosis. Additionally, clinicopathological features data was also extracted from these studies.

Conclusions: High expression level of Flotillin-1 protein was correlated with poorer clinical outcome. It might serve as a prognostic biomarker and a potential predictive factor of clinicopathology in various tumors. Further well-designed clinical studies should be performed to verify the clinical utility of Flotillin-1 in human solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17075